NCT06868238View on ClinicalTrials.gov

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2029

Conditions

Ductal Carcinoma in Situ

Interventions

DRUG

Magtrace

Participants will receive a single injection of Magtrace into the breast during their mastectomy.

All Listed Sponsors

lead

University of Florida

OTHER